Window of Opportunity Trial of Abemaciclib for Bladder CancerWeill Medical College of Cornell University / Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT03837821
Abemaciclib PubChem CID: 46220502
Investigators at Weill Medical College of Cornell University have opened a Phase I “Window of Opportunity” clinical trial of neoadjuvant abemaciclib (Verzenio®, Eli Lilly and Company) followed by radical cystectomy in patients with platinum-ineligible urothelial carcinoma (bladder cancer) to evaluate CDK4/6-dependent phosphorylation of pocket proteins and clonal evolution dynamics.
See complete details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to email@example.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.